Cellular Origins and Fresenius Kabi announced today that they signed a development agreement over cell and gene therapies (CGTs). The agreement leverages both companies’ expertise in CGTs. They aim to digitally and physically integrate Fresenius Kabi’s suite of cell therapy processing technologies with Cellular Origins’ CGT robotic manufacturing platform, Constellation. With this integration, the companies…